Macrophages	B-cell_type
in	O
human	O
atheroma	O
contain	O
PPARgamma	B-protein
:	O
differentiation-dependent	B-protein
peroxisomal	I-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
expression	O
and	O
reduction	O
of	O
MMP-9	B-protein
activity	O
through	O
PPARgamma	B-protein
activation	O
in	O
mononuclear	O
phagocytes	O
in	O
vitro	O
.	O

Mononuclear	B-cell_type
phagocytes	I-cell_type
play	O
an	O
important	O
role	O
in	O
atherosclerosis	O
and	O
its	O
sequela	O
plaque	O
rupture	O
in	O
part	O
by	O
their	O
secretion	O
of	O
matrix	B-protein
metalloproteinases	I-protein
(	O
MMPs	B-protein
)	O
,	O
including	O
MMP-9	B-protein
.	O

Peroxisomal	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
in	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
various	O
activators	O
,	O
including	O
15-deoxy-delta12	O
,	O
14-prostaglandin	O
J2	O
and	O
the	O
antidiabetic	O
agent	O
troglitazone	O
.	O

The	O
role	O
of	O
PPARgamma	B-protein
in	O
human	O
atherosclerosis	O
is	O
unexplored	O
.	O

We	O
report	O
here	O
that	O
monocytes/macrophages	B-cell_type
in	O
human	O
atherosclerotic	O
lesions	O
(	O
n	O
=	O
12	O
)	O
express	O
immunostainable	B-protein
PPARgamma	I-protein
.	O

Normal	O
artery	O
specimens	O
(	O
n	O
=	O
6	O
)	O
reveal	O
minimal	B-protein
immunoreactive	I-protein
PPARgamma	I-protein
.	O

Human	B-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
cultured	O
for	O
6	O
days	O
in	O
5	O
%	O
human	O
serum	O
expressed	O
PPARgamma	B-RNA
mRNA	I-RNA
and	O
protein	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
PPARgamma	B-RNA
mRNA	I-RNA
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
increased	O
during	O
phorbol	O
12-myristate	O
13	O
acetate-induced	O
differentiation	O
.	O

Stimulation	O
of	O
PPARgamma	B-protein
with	O
troglitazone	O
or	O
15-deoxy-delta12	O
,	O
14-prostaglandin	O
J2	O
in	O
human	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
inhibited	O
MMP-9	B-protein
gelatinolytic	O
activity	O
in	O
a	O
concentration-dependent	O
fashion	O
as	O
revealed	O
by	O
zymography	O
.	O

This	O
inhibition	O
correlates	O
with	O
decreased	O
MMP-9	B-protein
secretion	O
as	O
determined	O
by	O
Western	O
blotting	O
.	O

Thus	O
,	O
PPARgamma	B-protein
is	O
present	O
in	O
macrophages	B-cell_type
in	O
human	O
atherosclerotic	O
lesions	O
and	O
may	O
regulate	O
expression	O
and	O
activity	O
of	O
MMP-9	B-protein
,	O
an	O
enzyme	O
implicated	O
in	O
plaque	O
rupture	O
.	O

PPARgamma	B-protein
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
monocyte/macrophage	O
function	O
with	O
relevance	O
for	O
human	O
atherosclerotic	O
disease	O
.	O

Short	NULL
Communication	NULL
American	NULL
Journal	NULL
of	NULL
Pathology	NULL
,	NULL
Vol	NULL
.	NULL

153	NULL
,	NULL
No	NULL
.	NULL

1	NULL
,	NULL
July	NULL
1998	NULL
Copyright	NULL
©	NULL
American	NULL
Society	NULL
for	NULL
Investigative	NULL
Pathology	NULL
Macrophages	NULL
in	NULL
Human	NULL
Atheroma	NULL
Contain	NULL
PPARy	NULL
Differentiation-Dependent	NULL
Peroxisomal	NULL
Proliferator-Activated	NULL
Receptor	NULL
y	NULL
(	NULL
PPARy	NULL
)	NULL
Expression	NULL
and	NULL
Reduction	NULL
of	NULL
MMP-9	NULL
Activity	NULL
through	NULL
PPARy	NULL
Activation	NULL
in	NULL
Mononuclear	NULL
Phagocytes	NULL
in	NULL
Vitro	NULL
Nikolaus	NULL
Marx	NULL
,	NULL
Galina	NULL
Sukhova	NULL
,	NULL
Curran	NULL
Murphy	NULL
,	NULL
Peter	NULL
Libby	NULL
,	NULL
and	NULL
Jorge	NULL
Plutzky	NULL
From	NULL
the	NULL
Vascular	NULL
Medicine	NULL
and	NULL
Atherosclerosis	NULL
Unit	NULL
,	NULL
Cardiovascular	NULL
Division	NULL
,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
Mononuclear	NULL
phagocytes	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
atherosclerosis	NULL
and	NULL
its	NULL
sequela	NULL
plaque	NULL
rupture	NULL
in	NULL
part	NULL
by	NULL
their	NULL
secretion	NULL
of	NULL
matrix	NULL
metalloproteinases	NULL
(	NULL
MMPs	NULL
)	NULL
,	NULL
including	NULL
MMP-9	NULL
.	NULL

Peroxisomal	NULL
proliferator-activated	NULL
receptor	NULL
y	NULL
(	NULL
PPARy	NULL
)	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
in	NULL
the	NULL
nuclear	NULL
receptor	NULL
superfamily	NULL
,	NULL
regulates	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
various	NULL
activators	NULL
,	NULL
including	NULL
15-deoxy-~	NULL
``	NULL
``	NULL
*-prostaglandin	NULL
J	NULL
,	NULL
and	NULL
the	NULL
antidiabetic	NULL
agent	NULL
troglitazone	NULL
.	NULL

The	NULL
role	NULL
of	NULL
PPARy	NULL
in	NULL
human	NULL
atherosclerosis	NULL
is	NULL
unexplored	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
monocytes/macrophages	NULL
in	NULL
human	NULL
atherosclerotic	NULL
lesions	NULL
(	NULL
#	NULL
=	NULL
12	NULL
)	NULL
express	NULL
immunostainable	NULL
PPARy	NULL
.	NULL

Normal	NULL
artery	NULL
specimens	NULL
(	NULL
#	NULL
=	NULL
6	NULL
)	NULL
reveal	NULL
minimal	NULL
immunoreactive	NULL
PPARy	NULL
.	NULL

Human	NULL
monocytes	NULL
and	NULL
monocyte-derived	NULL
macrophages	NULL
cultured	NULL
for	NULL
6	NULL
days	NULL
in	NULL
5	NULL
%	NULL
human	NULL
serum	NULL
expressed	NULL
PPARy	NULL
mRNA	NULL
and	NULL
protein	NULL
by	NULL
reverse	NULL
transcription-polymerase	NULL
chain	NULL
reaction	NULL
and	NULL
Western	NULL
blotting	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
PPARy	NULL
mRNA	NULL
expression	NULL
in	NULL
U937	NULL
cells	NULL
increased	NULL
during	NULL
phorbol	NULL
12-myristate	NULL
13	NULL
acetate-induced	NULL
differentiation	NULL
.	NULL

Stimulation	NULL
of	NULL
PPARy	NULL
with	NULL
troglitazone	NULL
or	NULL
15-deoxy-*	NULL
'	NULL
``	NULL
``	NULL
*-prostaglandin	NULL
J	NULL
,	NULL
in	NULL
human	NULL
monocyte-derived	NULL
macrophages	NULL
inhibited	NULL
MMP-9	NULL
gelatinolytic	NULL
activity	NULL
in	NULL
a	NULL
concentration-dependent	NULL
fashion	NULL
as	NULL
revealed	NULL
by	NULL
zymography	NULL
.	NULL

This	NULL
inhibition	NULL
correlates	NULL
with	NULL
decreased	NULL
MMP-9	NULL
secretion	NULL
as	NULL
determined	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

Thus	NULL
,	NULL
PPARy	NULL
is	NULL
present	NULL
in	NULL
macrophages	NULL
in	NULL
human	NULL
atherosclerotic	NULL
lesions	NULL
and	NULL
may	NULL
regulate	NULL
expression	NULL
and	NULL
activity	NULL
of	NULL
MMP-9	NULL
,	NULL
an	NULL
enzyme	NULL
implicated	NULL
in	NULL
plaque	NULL
rupture	NULL
.	NULL

PPAR	NULL
»	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
an	NULL
important	NULL
regulator	NULL
of	NULL
monocyte/macrophage	NULL
function	NULL
with	NULL
relevance	NULL
for	NULL
human	NULL
atherosclerotic	NULL
disease	NULL
.	NULL

(	NULL
Am	NULL
J	NULL
Pathol	NULL
1998	NULL
,	NULL
153:17-23	NULL
)	NULL
Macrophages	NULL
influence	NULL
many	NULL
aspects	NULL
of	NULL
atherosclerosis	NULL
,	NULL
including	NULL
the	NULL
vulnerability	NULL
of	NULL
plaques	NULL
to	NULL
undergo	NULL
disruption	NULL
and	NULL
thrombosis	NULL
.	NULL

'*	NULL
Pathological	NULL
studies	NULL
have	NULL
shown	NULL
abundant	NULL
macrophages	NULL
in	NULL
ruptured	NULL
atheroma	NULL
.	NULL
``	NULL

In	NULL
vitro	NULL
biomechanical	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
fibrous	NULL
cap	NULL
of	NULL
macrophage-rich	NULL
plaques	NULL
has	NULL
reduced	NULL
tensile	NULL
strength	NULL
.	NULL

The	NULL
role	NULL
of	NULL
macrophages	NULL
in	NULL
plaque	NULL
rupture	NULL
may	NULL
involve	NULL
secretion	NULL
of	NULL
matrix	NULL
metalloproteinases	NULL
(	NULL
MMPs	NULL
)	NULL
,	NULL
enzymes	NULL
that	NULL
participate	NULL
in	NULL
extracellular	NULL
matrix	NULL
degradation	NULL
.	NULL
``	NULL

MMP-9	NULL
,	NULL
also	NULL
referred	NULL
to	NULL
as	NULL
gelatinase	NULL
B	NULL
,	NULL
is	NULL
the	NULL
predominant	NULL
MMP	NULL
secreted	NULL
by	NULL
monocytes/macrophages	NULL
in	NULL
vitro	NULL
.	NULL

A	NULL
number	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
found	NULL
in	NULL
atheroma	NULL
can	NULL
augment	NULL
MMP-9	NULL
expression	NULL
by	NULL
mononuclear	NULL
phagocytes	NULL
,	NULL
including	NULL
interleukin	NULL
1	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
«	NULL
,	NULL
°	NULL
and	NULL
CD40	NULL
ligand	NULL
.	NULL
``	NULL

''	NULL
Nonetheless	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
atheroma	NULL
are	NULL
stable	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
inhibitors	NULL
of	NULL
MMP-9	NULL
expression	NULL
must	NULL
be	NULL
at	NULL
work	NULL
,	NULL
opposing	NULL
the	NULL
effects	NULL
of	NULL
proinflammatory	NULL
mediators	NULL
in	NULL
the	NULL
plaque	NULL
.	NULL

We	NULL
therefore	NULL
undertook	NULL
an	NULL
effort	NULL
to	NULL
identify	NULL
endogenous	NULL
inhibitors	NULL
of	NULL
MMP-9	NULL
expression	NULL
.	NULL

Work	NULL
from	NULL
other	NULL
groups	NULL
has	NULL
established	NULL
that	NULL
activation	NULL
of	NULL
various	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
can	NULL
inhibit	NULL
MMP	NULL
expression	NULL
through	NULL
a	NULL
variety	NULL
of	NULL
mechanisms	NULL
.	NULL
``	NULL

''	NULL
Interest	NULL
is	NULL
growing	NULL
regarding	NULL
Supported	NULL
by	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
Grant	NULL
MA	NULL
2047/1-1	NULL
(	NULL
to	NULL
NM	NULL
)	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
HL	NULL
03107	NULL
and	NULL
P5OHL56985	NULL
(	NULL
to	NULL
JP	NULL
)	NULL
,	NULL
and	NULL
P5OHL56985	NULL
and	NULL
RS7HL34636	NULL
(	NULL
to	NULL
PL	NULL
)	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
April	NULL
2	NULL
,	NULL
1998	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Jorge	NULL
Plutzky	NULL
,	NULL
Vascular	NULL
Medicine	NULL
and	NULL
Atherosclerosis	NULL
Unit	NULL
,	NULL
Cardiovascular	NULL
Division	NULL
,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
221	NULL
Longwood	NULL
Avenue	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

E-mail	NULL
:	NULL
jplutzky	NULL
@	NULL
bics.bwh.harvard.edu	NULL
.	NULL

17	NULL
18	NULL
_	NULL
Marx	NULL
et	NULL
al	NULL
AJP	NULL
July	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

153	NULL
,	NULL
No	NULL
.	NULL

1	NULL
the	NULL
role	NULL
of	NULL
peroxisomal	NULL
proliferation	NULL
activator	NULL
receptors	NULL
(	NULL
PPARs	NULL
)	NULL
,	NULL
a	NULL
subgroup	NULL
of	NULL
the	NULL
nuclear	NULL
receptor	NULL
superfamily	NULL
,	NULL
as	NULL
transcriptional	NULL
mediators	NULL
.	NULL
``	NULL

One	NULL
of	NULL
these	NULL
,	NULL
PPARy	NULL
,	NULL
has	NULL
been	NULL
implicated	NULL
as	NULL
a	NULL
``	NULL
master	NULL
regulator	NULL
``	NULL
of	NULL
lipid	NULL
metabolism	NULL
and	NULL
adipogenesis	NULL
;	NULL
ectopic	NULL
overexpression	NULL
of	NULL
PPARy	NULL
in	NULL
fibroblasts	NULL
redirects	NULL
these	NULL
cells	NULL
into	NULL
an	NULL
adipo-genic	NULL
program	NULL
.	NULL

'*	NULL
``	NULL
``	NULL
Like	NULL
other	NULL
nuclear	NULL
receptors	NULL
,	NULL
PPARy	NULL
contains	NULL
a	NULL
ligand	NULL
binding	NULL
domain	NULL
and	NULL
a	NULL
central	NULL
DNA	NULL
binding	NULL
domain	NULL
,	NULL
which	NULL
interacts	NULL
with	NULL
PPAR	NULL
response	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
target	NULL
genes	NULL
.	NULL

'®	NULL
Specific	NULL
activators	NULL
identified	NULL
thus	NULL
far	NULL
include	NULL
both	NULL
the	NULL
naturally	NULL
occurring	NULL
prostaglandin	NULL
D	NULL
metabolite	NULL
15-deoxy-~	NULL
'	NULL
2'*-pros-taglandin	NULL
J	NULL
,	NULL
(	NULL
15	NULL
d-PGJ	NULL
,	NULL
)	NULL
!	NULL

``	NULL
'°	NULL
and	NULL
the	NULL
synthetic	NULL
antidiabetic	NULL
agent	NULL
troglitazone	NULL
.	NULL

``	NULL
``	NULL
~	NULL
``	NULL
The	NULL
role	NULL
of	NULL
PPARy	NULL
in	NULL
nonadipocytes	NULL
has	NULL
received	NULL
little	NULL
attention	NULL
,	NULL
although	NULL
expression	NULL
had	NULL
been	NULL
previously	NULL
noted	NULL
in	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
Recent	NULL
work	NULL
suggests	NULL
PPARy	NULL
stimulation	NULL
can	NULL
inhibit	NULL
both	NULL
cytokine-induced	NULL
activation	NULL
of	NULL
macro-phages	NULL
``	NULL
*	NULL
and	NULL
in	NULL
vitro	NULL
expression	NULL
of	NULL
transfected	NULL
promoter	NULL
constructs	NULL
of	NULL
genes	NULL
implicated	NULL
in	NULL
atherogenesis	NULL
,	NULL
including	NULL
MMP-9.2°	NULL
The	NULL
present	NULL
study	NULL
tested	NULL
the	NULL
hypotheses	NULL
1	NULL
)	NULL
that	NULL
macrophages	NULL
in	NULL
human	NULL
atheroma	NULL
express	NULL
PPARy	NULL
,	NULL
2	NULL
)	NULL
that	NULL
this	NULL
novel	NULL
nuclear	NULL
receptor	NULL
is	NULL
regulated	NULL
during	NULL
differentiation	NULL
of	NULL
monocytes	NULL
into	NULL
macrophages	NULL
,	NULL
and	NULL
3	NULL
)	NULL
that	NULL
PPARy	NULL
activation	NULL
can	NULL
limit	NULL
MMP-9	NULL
expression	NULL
and	NULL
enzymatic	NULL
activity	NULL
by	NULL
these	NULL
cells	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Immunohistochemistry	NULL
Surgical	NULL
specimens	NULL
of	NULL
human	NULL
carotid	NULL
atherosclerotic	NULL
lesions	NULL
were	NULL
obtained	NULL
by	NULL
protocols	NULL
approved	NULL
by	NULL
the	NULL
Human	NULL
Investigation	NULL
Review	NULL
Committee	NULL
at	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
.	NULL

Serial	NULL
cryostat	NULL
sections	NULL
(	NULL
5	NULL
mm	NULL
)	NULL
were	NULL
cut	NULL
,	NULL
air	NULL
dried	NULL
onto	NULL
microscopic	NULL
slides	NULL
,	NULL
and	NULL
fixed	NULL
in	NULL
acetone	NULL
at	NULL
-20°C	NULL
for	NULL
5	NULL
minutes	NULL
.	NULL

Staining	NULL
for	NULL
PPARy	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
anti-human	NULL
PPARy	NULL
peptide	NULL
antibody	NULL
'	NULL
``	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
Mitchell	NULL
Lazar	NULL
,	NULL
University	NULL
of	NULL
Pennsylvania	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Philadelphia	NULL
)	NULL
.	NULL

Macrophages	NULL
were	NULL
identified	NULL
by	NULL
staining	NULL
with	NULL
anti-CD68	NULL
antibody	NULL
(	NULL
DAKO	NULL
,	NULL
Carpinteria	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Sections	NULL
were	NULL
preincubated	NULL
with	NULL
PBS	NULL
containing	NULL
0.3	NULL
%	NULL
hydrogen	NULL
peroxidase	NULL
activity	NULL
and	NULL
stained	NULL
for	NULL
1	NULL
hour	NULL
with	NULL
primary	NULL
antibody	NULL
diluted	NULL
in	NULL
PBS	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
appropriate	NULL
serum	NULL
.	NULL

Negative	NULL
control	NULL
was	NULL
performed	NULL
by	NULL
preabsorbing	NULL
the	NULL
anti-PPARy	NULL
antibodies	NULL
with	NULL
the	NULL
peptide	NULL
from	NULL
which	NULL
the	NULL
antibody	NULL
was	NULL
derived	NULL
and	NULL
subsequently	NULL
using	NULL
these	NULL
``	NULL
peptide-blocked	NULL
PPARy	NULL
antibodies	NULL
``	NULL
at	NULL
concentrations	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
experimental	NULL
conditions	NULL
.	NULL

Finally	NULL
,	NULL
sections	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
respective	NULL
bio-tinylated	NULL
secondary	NULL
antibody	NULL
(	NULL
Vector	NULL
Laboratories	NULL
,	NULL
Bur-lingame	NULL
,	NULL
CA	NULL
)	NULL
followed	NULL
by	NULL
avidin-biotin-peroxidase	NULL
complex	NULL
(	NULL
Vectastain	NULL
ABC	NULL
kit	NULL
,	NULL
Vector	NULL
Laboratories	NULL
)	NULL
.	NULL

Antibody	NULL
binding	NULL
was	NULL
visualized	NULL
with	NULL
3-amino-9-ethyl	NULL
carbazole	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
or	NULL
with	NULL
True	NULL
Blue	NULL
Peroxidase	NULL
substrate	NULL
(	NULL
Kirkegaard	NULL
&	NULL
Perry	NULL
Laboratories	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Sections	NULL
were	NULL
counterstained	NULL
with	NULL
Gill	NULL
's	NULL
Hematox-ylin	NULL
or	NULL
Contrast	NULL
Red	NULL
(	NULL
Kirkegaard	NULL
&	NULL
Perry	NULL
Laboratories	NULL
)	NULL
.	NULL

Computer-assisted	NULL
image	NULL
analysis	NULL
was	NULL
used	NULL
to	NULL
quantify	NULL
staining	NULL
on	NULL
sections	NULL
using	NULL
Optimas	NULL
5.2	NULL
software	NULL
.	NULL

Percentage	NULL
area	NULL
of	NULL
positive	NULL
staining	NULL
for	NULL
PPARy	NULL
or	NULL
CD68	NULL
in	NULL
the	NULL
shoulders	NULL
of	NULL
the	NULL
plaques	NULL
,	NULL
defined	NULL
as	NULL
the	NULL
intimal	NULL
regions	NULL
flanking	NULL
the	NULL
lipid	NULL
core	NULL
,	NULL
was	NULL
compared	NULL
with	NULL
the	NULL
percentage	NULL
area	NULL
of	NULL
positive	NULL
staining	NULL
in	NULL
other	NULL
zones	NULL
of	NULL
the	NULL
sec-tions	NULL
.	NULL

Cell	NULL
Culture	NULL
Human	NULL
monocytes	NULL
were	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
volunteers	NULL
by	NULL
sequential	NULL
gradient	NULL
centrifugation	NULL
with	NULL
Lymphocyte	NULL
Separation	NULL
Medium	NULL
(	NULL
Organon	NULL
Tech-nika	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
and	NULL
One	NULL
Step	NULL
Monocytes	NULL
(	NULL
Accurate	NULL
Chemical	NULL
and	NULL
Scientific	NULL
Co.	NULL
,	NULL
Westbury	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Monocytes	NULL
were	NULL
plated	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
3	NULL
X	NULL
10°	NULL
cells/L	NULL
in	NULL
serum-free	NULL
M199	NULL
medium	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
isolated	NULL
by	NULL
adherence	NULL
to	NULL
plastic	NULL
dishes	NULL
at	NULL
37°C	NULL
.	NULL

Nonadherent	NULL
cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
Hanks	NULL
'	NULL
buffer	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
and	NULL
the	NULL
remaining	NULL
adherent	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
M199	NULL
medium	NULL
with	NULL
5	NULL
%	NULL
human	NULL
serum	NULL
at	NULL
37°C/5	NULL
%	NULL
CO	NULL
,	NULL
;	NULL
.	NULL

Medium	NULL
was	NULL
changed	NULL
every	NULL
2	NULL
days	NULL
for	NULL
6	NULL
days	NULL
,	NULL
and	NULL
resulting	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
``	NULL
monocyte-derived	NULL
macrophages	NULL
.	NULL
``	NULL

In	NULL
some	NULL
ex-periments	NULL
,	NULL
monocytes	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
days	NULL
with	NULL
5	NULL
%	NULL
human	NULL
serum	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
PPARy	NULL
activators	NULL
troglitazone	NULL
(	NULL
provided	NULL
by	NULL
Parke	NULL
Davis	NULL
(	NULL
Morris	NULL
Plains	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
dissolved	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
instructions	NULL
)	NULL
or	NULL
15	NULL
d-PGJ	NULL
,	NULL
(	NULL
CalbioChem	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
at	NULL
concentrations	NULL
indicated	NULL
.	NULL

After	NULL
6	NULL
days	NULL
,	NULL
cells	NULL
were	NULL
changed	NULL
to	NULL
serum-free	NULL
conditions	NULL
,	NULL
and	NULL
supernatants	NULL
were	NULL
collected	NULL
after	NULL
24	NULL
hours	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

The	NULL
human	NULL
monocyte-like	NULL
cell	NULL
line	NULL
U937	NULL
,	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
,	NULL
was	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
BioWhittaker	NULL
)	NULL
with	NULL
1	NULL
%	NULL
glu-tamine	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
1	NULL
%	NULL
penicillin-streptomycin	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

RNA	NULL
Extraction	NULL
and	NULL
Reverse	NULL
Transcription-Polymerase	NULL
Chain	NULL
Reaction	NULL
Total	NULL
RNA	NULL
from	NULL
10	NULL
``	NULL
cells	NULL
was	NULL
isolated	NULL
by	NULL
the	NULL
single-step	NULL
guanidium	NULL
thiocyanate-phenol-chloroform	NULL
method	NULL
using	NULL
RNAzol	NULL
from	NULL
Tel-Test	NULL
(	NULL
Friendswood	NULL
,	NULL
TX	NULL
)	NULL
.	NULL

Two	NULL
micrograms	NULL
of	NULL
total	NULL
RNA	NULL
was	NULL
reverse-transcribed	NULL
into	NULL
cDNA	NULL
with	NULL
1	NULL
U/ml	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Superscript	NULL
,	NULL
Life	NULL
Technologies	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
hour	NULL
in	NULL
standard	NULL
buffer	NULL
.	NULL

For	NULL
the	NULL
amplification	NULL
of	NULL
PPARy	NULL
cDNA	NULL
,	NULL
two	NULL
oligonucleotide	NULL
primers	NULL
were	NULL
designed	NULL
from	NULL
nucleotides	NULL
+235	NULL
to	NULL
708	NULL
(	NULL
a	NULL
473-bp	NULL
fragment	NULL
)	NULL
:	NULL
sense	NULL
primer	NULL
,	NULL
5'-TCTCTCCGTAATG-GAAGACC-3	NULL
'	NULL
;	NULL
anti-sense	NULL
primer	NULL
,	NULL
5'-CCCCTACAGAG-TATTACG-3	NULL
'	NULL
.	NULL

The	NULL
polymerase	NULL
chain	NULL
reaction	NULL
reaction	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
a	NULL
standard	NULL
buffer	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
with	NULL
200	NULL
ng	NULL
of	NULL
each	NULL
primer	NULL
(	NULL
IDT	NULL
,	NULL
Coralville	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
33	NULL
mmol/L	NULL
MgCl	NULL
,	NULL
and	NULL
0.5	NULL
U	NULL
Taq	NULL
polymerase	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
for	NULL
30	NULL
cycles	NULL
.	NULL

Polymerase	NULL
chain	NULL
reaction	NULL
products	NULL
(	NULL
10	NULL
w//25ul	NULL
reaction	NULL
)	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

Northern	NULL
Blot	NULL
Analysis	NULL
Five	NULL
micrograms	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
undifferentiated	NULL
and	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
-differentiated	NULL
U937	NULL
cells	NULL
was	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
on	NULL
a	NULL
1.2	NULL
%	NULL
agarose	NULL
gel	NULL
and	NULL
transferred	NULL
using	NULL
traditional	NULL
Northern	NULL
blotting	NULL
techniques	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
ultraviolet-crosslinked	NULL
,	NULL
prehybridized	NULL
at	NULL
42°C	NULL
(	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
5	NULL
%	NULL
Denhardt	NULL
's	NULL
solution	NULL
,	NULL
5X	NULL
standard	NULL
saline	NULL
citrate	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
,	NULL
and	NULL
20	NULL
mmol/L	NULL
salmon	NULL
sperm	NULL
DNA	NULL
)	NULL
,	NULL
and	NULL
hybridized	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
with	NULL
a	NULL
random	NULL
primed	NULL
radiolabeled	NULL
(	NULL
[	NULL
«	NULL
-P°	NULL
``	NULL
]	NULL
dCTP	NULL
)	NULL
Sal-1	NULL
fragment	NULL
of	NULL
pCMX-PPARy	NULL
(	NULL
generously	NULL
provided	NULL
by	NULL
Dr.	NULL
Bruce	NULL
Spiegelman	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

'*	NULL
The	NULL
membranes	NULL
were	NULL
washed	NULL
at	NULL
60°C	NULL
in	NULL
1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate/2x	NULL
standard	NULL
saline	NULL
citrate	NULL
and	NULL
exposed	NULL
(	NULL
1-3	NULL
days	NULL
,	NULL
-70°C	NULL
)	NULL
to	NULL
Kodak	NULL
X-OMAT	NULL
film	NULL
with	NULL
an	NULL
intensifying	NULL
screen	NULL
.	NULL

Preparation	NULL
of	NULL
Nuclear	NULL
and	NULL
Cytosolic	NULL
Extracts	NULL
and	NULL
Western	NULL
Blot	NULL
Analysis	NULL
For	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
a	NULL
positive	NULL
control	NULL
was	NULL
generated	NULL
by	NULL
transiently	NULL
transfecting	NULL
a	NULL
PPARy	NULL
expression	NULL
con-struct	NULL
,	NULL
pCMX-PPARy	NULL
,	NULL
'*	NULL
into	NULL
human	NULL
skin	NULL
fibroblasts	NULL
using	NULL
lipofectamine	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
.	NULL

Nuclear	NULL
and	NULL
cytosolic	NULL
extracts	NULL
of	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
prepared	NULL
separately	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
10	NULL
mmol/L	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1.5	NULL
mmol/L	NULL
MgCl	NULL
,	NULL
10	NULL
mmol/L	NULL
KCI	NULL
,	NULL
and	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
.	NULL

Nuclei	NULL
were	NULL
pelleted	NULL
at	NULL
13,000	NULL
x	NULL
g	NULL
for	NULL
5	NULL
minutes	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
supernatant	NULL
was	NULL
used	NULL
as	NULL
the	NULL
cytosolic	NULL
fraction	NULL
.	NULL

Nuclei	NULL
were	NULL
lysed	NULL
in	NULL
20	NULL
mmol/L	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1.5	NULL
mmol/L	NULL
MgCl	NULL
,	NULL
,	NULL
420	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
and	NULL
0.2	NULL
mmol/L	NULL
ethylenediaminetetraac-etate	NULL
.	NULL

After	NULL
centrifugation	NULL
at	NULL
13,000	NULL
x	NULL
g	NULL
for	NULL
5	NULL
minutes	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
diluted	NULL
in	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
20	NULL
mmol/L	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
100	NULL
mmol/L	NULL
KCI	NULL
,	NULL
0.2	NULL
mmol/L	NULL
ethyl-enediaminetetraacetate	NULL
,	NULL
and	NULL
20	NULL
%	NULL
glycerol	NULL
and	NULL
used	NULL
as	NULL
nuclear	NULL
extract	NULL
.	NULL

Protein	NULL
concentration	NULL
of	NULL
nuclear	NULL
and	NULL
cys-tolic	NULL
extracts	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
protein	NULL
assay	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Processed	NULL
samples	NULL
were	NULL
applied	NULL
to	NULL
10	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
gels	NULL
,	NULL
and	NULL
protein	NULL
was	NULL
transferred	NULL
to	NULL
nitrocel-lulose	NULL
membranes	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
using	NULL
semi-dry	NULL
blotting	NULL
for	NULL
1	NULL
hour	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Membranes	NULL
were	NULL
blocked	NULL
overnight	NULL
in	NULL
Tris-buffered	NULL
saline-Tween	NULL
with	NULL
5	NULL
%	NULL
dry	NULL
milk	NULL
and	NULL
incubated	NULL
with	NULL
goat	NULL
anti-human	NULL
PPARy	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
N-20	NULL
,	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
membranes	NULL
were	NULL
stained	NULL
with	NULL
horseradigh-con-jugated	NULL
rabbit	NULL
anti-goat	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

Antigen	NULL
detection	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
chemiluminescent	NULL
detection	NULL
system	NULL
(	NULL
NEN	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Similar	NULL
methods	NULL
were	NULL
used	NULL
to	NULL
perform	NULL
Western	NULL
blots	NULL
on	NULL
MMP-9	NULL
in	NULL
monocyte-derived	NULL
macrophage	NULL
supernatants	NULL
using	NULL
a	NULL
specific	NULL
rabbit	NULL
anti-human	NULL
MMP-9	NULL
antibody	NULL
(	NULL
Oncogene	NULL
Science	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Macrophages	NULL
in	NULL
Human	NULL
Atheroma	NULL
Express	NULL
PPARy	NULL
-	NULL
19	NULL
AJP	NULL
July	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

153	NULL
,	NULL
No	NULL
.	NULL

1	NULL
Substrate	NULL
Gel	NULL
Zymography	NULL
Gelatinolytic	NULL
activity	NULL
of	NULL
MMP-9	NULL
from	NULL
conditioned	NULL
medium	NULL
(	NULL
10	NULL
wl/500	NULL
pl	NULL
total	NULL
supernatant	NULL
loaded	NULL
)	NULL
of	NULL
monocytes	NULL
or	NULL
monocyte-derived	NULL
macrophages	NULL
was	NULL
analyzed	NULL
by	NULL
zymography	NULL
on	NULL
gelatin-containing	NULL
polyacrylamide	NULL
.	NULL
'	NULL

''	NULL
Equal	NULL
amounts	NULL
were	NULL
loaded	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

After	NULL
washing	NULL
in	NULL
2.5	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
gels	NULL
were	NULL
incubated	NULL
overnight	NULL
at	NULL
37°C	NULL
in	NULL
50	NULL
mmol/L	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
containing	NULL
CaCl	NULL
,	NULL
and	NULL
0.05	NULL
%	NULL
Brij	NULL
35	NULL
.	NULL

Gels	NULL
were	NULL
stained	NULL
in	NULL
0.1	NULL
%	NULL
Colloidal	NULL
Brilliant	NULL
Blue	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
10	NULL
%	NULL
acetic	NULL
acid	NULL
,	NULL
and	NULL
40	NULL
%	NULL
methanol	NULL
for	NULL
2	NULL
hours	NULL
and	NULL
destained	NULL
in	NULL
10	NULL
%	NULL
acetic	NULL
acid	NULL
and	NULL
40	NULL
%	NULL
methanol	NULL
.	NULL

Proteins	NULL
having	NULL
gelatinolytic	NULL
activity	NULL
were	NULL
visualized	NULL
as	NULL
clear	NULL
zones	NULL
in	NULL
an	NULL
otherwise	NULL
blue	NULL
gel	NULL
.	NULL

Photographs	NULL
of	NULL
the	NULL
gels	NULL
were	NULL
scanned	NULL
by	NULL
an	NULL
imaging	NULL
densitometer	NULL
and	NULL
quantified	NULL
using	NULL
the	NULL
NIH	NULL
Image	NULL
1.6	NULL
software	NULL
program	NULL
.	NULL

To	NULL
ensure	NULL
that	NULL
differences	NULL
in	NULL
protein	NULL
amounts	NULL
did	NULL
not	NULL
account	NULL
for	NULL
the	NULL
differences	NULL
seen	NULL
,	NULL
the	NULL
zymographic	NULL
data	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
protein	NULL
applied	NULL
to	NULL
each	NULL
lane	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
protein	NULL
did	NULL
not	NULL
vary	NULL
significantly	NULL
from	NULL
sample	NULL
to	NULL
sample	NULL
.	NULL

Results	NULL
Macrophages	NULL
in	NULL
Human	NULL
Atheroma	NULL
Contain	NULL
PPARy	NULL
Analysis	NULL
of	NULL
human	NULL
carotid	NULL
atheroma	NULL
(	NULL
n	NULL
=	NULL
12	NULL
)	NULL
demonstrated	NULL
immunoreactive	NULL
PPARy	NULL
co-localizing	NULL
with	NULL
macrophages	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
A	NULL
and	NULL
C	NULL
)	NULL
,	NULL
so	NULL
identified	NULL
by	NULL
morphology	NULL
and	NULL
by	NULL
staining	NULL
of	NULL
parallel	NULL
sections	NULL
with	NULL
the	NULL
macrophage-specific	NULL
antibody	NULL
anti-CD68	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

PPARy	NULL
staining	NULL
was	NULL
mainly	NULL
localized	NULL
in	NULL
the	NULL
macrophage-rich	NULL
shoulder	NULL
region	NULL
of	NULL
the	NULL
plaque	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
,	NULL
with	NULL
35	NULL
+	NULL
5	NULL
%	NULL
of	NULL
this	NULL
area	NULL
positive	NULL
for	NULL
PPARy	NULL
and	NULL
54	NULL
+	NULL
6	NULL
%	NULL
positive	NULL
for	NULL
macrophages	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
color	NULL
image	NULL
analysis	NULL
.	NULL

Quantification	NULL
of	NULL
staining	NULL
in	NULL
nonshoulder	NULL
regions	NULL
revealed	NULL
a	NULL
2	NULL
+	NULL
1	NULL
%	NULL
area	NULL
positive	NULL
for	NULL
PPARy	NULL
and	NULL
8	NULL
+	NULL
1	NULL
%	NULL
for	NULL
macrophages	NULL
.	NULL

Preabsorption	NULL
of	NULL
anti-PPARy	NULL
antibodies	NULL
with	NULL
the	NULL
peptide	NULL
antigen	NULL
abrogated	NULL
staining	NULL
in	NULL
adjacent	NULL
sections	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
im-munostaining	NULL
.	NULL

Higher-power	NULL
views	NULL
of	NULL
PPARy-stained	NULL
plaque	NULL
(	NULL
indicated	NULL
by	NULL
the	NULL
rectangle	NULL
in	NULL
Figure	NULL
1A	NULL
)	NULL
showed	NULL
staining	NULL
predominantly	NULL
in	NULL
nuclei	NULL
of	NULL
macrophages	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

Only	NULL
occasional	NULL
endothelial	NULL
cells	NULL
or	NULL
smooth	NULL
muscle	NULL
cells	NULL
in	NULL
lesions	NULL
showed	NULL
immunoreactive	NULL
PPARy	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Study	NULL
of	NULL
nonatheromatous	NULL
arterial	NULL
specimens	NULL
{	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
showed	NULL
scant	NULL
PPARy	NULL
in	NULL
nuclei	NULL
of	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
.	NULL

Cells	NULL
of	NULL
the	NULL
Monocyte/Macrophage	NULL
Lineage	NULL
Express	NULL
PPARy	NULL
mRNA	NULL
and	NULL
Protein	NULL
Freshly	NULL
prepared	NULL
monocytes	NULL
,	NULL
monocyte-derived	NULL
macrophages	NULL
,	NULL
and	NULL
PMA-treated	NULL
U937	NULL
cells	NULL
all	NULL
contained	NULL
PPARy	NULL
mRNA	NULL
as	NULL
detected	NULL
by	NULL
a	NULL
473-bp	NULL
reverse	NULL
transcription-polymerase	NULL
chain	NULL
reaction	NULL
product	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

For	NULL
the	NULL
detection	NULL
of	NULL
PPARy	NULL
protein	NULL
,	NULL
we	NULL
prepared	NULL
separate	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
fractions	NULL
of	NULL
the	NULL
20	NULL
-	NULL
Marx	NULL
et	NULL
al	NULL
AJP	NULL
July	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

153	NULL
,	NULL
No	NULL
.	NULL

1	NULL
Pre-abs	NULL
.	NULL

PPARy	NULL
jA	NULL
%	NULL
hea	NULL
FZ	NULL
>	NULL
Z	NULL
~	NULL
%	NULL
ii	NULL
.	NULL

W	NULL
‘	NULL
ill	NULL
“	NULL
>	NULL
t	NULL
/	NULL
%	NULL
;	NULL
e	NULL
A	NULL
L	NULL
}	NULL
,	NULL
u	NULL
;	NULL
``	NULL
x	NULL
35,1	NULL
»	NULL
xii	NULL
755-34	NULL
g	NULL
:	NULL
E*	NULL
*	NULL
it	NULL
?	NULL

e	NULL
:	NULL
w	NULL
.	NULL

:	NULL
r	NULL
’	NULL
§_	NULL
``	NULL
ex	NULL
``	NULL
5	NULL
``	NULL
~	NULL
>	NULL
``	NULL
I~	NULL
.	NULL

j	NULL
``	NULL
n	NULL
C	NULL
52,1	NULL
.	NULL

»	NULL
*	NULL
he	NULL
m	NULL
:	NULL
v	NULL
3	NULL
i	NULL
-	NULL
f*	NULL
PPARy	NULL
*~*	NULL
‘	NULL
C	NULL
%	NULL
is	NULL
It	NULL
»	NULL
.	NULL

a	NULL
#	NULL
}	NULL
“	NULL
‘	NULL
-	NULL
G	NULL
:	NULL
x	NULL
#	NULL
a	NULL
.	NULL

#	NULL
P-	NULL
€	NULL
.	NULL

»	NULL
o	NULL
é	NULL
‘	NULL
ﬂ	NULL
,	NULL
~	NULL
'	NULL
``	NULL
.	NULL

mo	NULL
*	NULL
%	NULL
.	NULL

®	NULL
IP	NULL
#	NULL
-	NULL
a	NULL
.	NULL

#	NULL
**	NULL
B	NULL
A	NULL
s	NULL
4	NULL
,	NULL
``	NULL
.-	NULL
-t	NULL
#	NULL
#	NULL
``	NULL
%	NULL
*	NULL
%	NULL
/	NULL
a	NULL
©	NULL
PPARy	NULL
&	NULL
'	NULL
J	NULL
?	NULL

-	NULL
PPARy	NULL
Figure	NULL
1	NULL
.	NULL

Expression	NULL
of	NULL
PPARy	NULL
in	NULL
human	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

A	NULL
:	NULL
Low-power	NULL
view	NULL
of	NULL
frozen	NULL
section	NULL
of	NULL
human	NULL
carotid	NULL
lesions	NULL
shows	NULL
immunoreactive	NULL
PPARy	NULL
next	NULL
to	NULL
the	NULL
lipid	NULL
core	NULL
in	NULL
the	NULL
shoulder	NULL
region	NULL
with	NULL
abundant	NULL
macrophages	NULL
present	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
other	NULL
atherosclerotic	NULL
specimens	NULL
(	NULL
x	NULL
=	NULL
12	NULL
)	NULL
.	NULL

B	NULL
:	NULL
No	NULL
immunoreactive	NULL
PPARy	NULL
is	NULL
detectable	NULL
in	NULL
parallel	NULL
sections	NULL
stained	NULL
with	NULL
PPARy	NULL
antibodies	NULL
preabsorbed	NULL
with	NULL
the	NULL
immunizing	NULL
peptide	NULL
,	NULL
indicating	NULL
that	NULL
staining	NULL
for	NULL
PPARy	NULL
in	NULL
(	NULL
A	NULL
)	NULL
and	NULL
(	NULL
C	NULL
)	NULL
is	NULL
specific	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
with	NULL
immunoglobulin	NULL
G	NULL
controls	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

C	NULL
:	NULL
High-power	NULL
view	NULL
of	NULL
the	NULL
area	NULL
indicated	NULL
by	NULL
the	NULL
rectangle	NULL
in	NULL
(	NULL
A	NULL
)	NULL
shows	NULL
PPARy	NULL
staining	NULL
restricted	NULL
to	NULL
macrophage	NULL
nuclei	NULL
(	NULL
see	NULL
quantification	NULL
in	NULL
Results	NULL
)	NULL
.	NULL

D	NULL
:	NULL
In	NULL
nonatherosclerotic	NULL
arteries	NULL
(	NULL
»	NULL
=	NULL
6	NULL
)	NULL
,	NULL
little	NULL
PPARy	NULL
could	NULL
be	NULL
detected	NULL
,	NULL
with	NULL
scant	NULL
staining	NULL
in	NULL
occasional	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

above-mentioned	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
untransfected	NULL
and	NULL
PPARy-transfected	NULL
fibroblasts	NULL
,	NULL
and	NULL
performed	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Nuclear	NULL
extracts	NULL
of	NULL
monocytes	NULL
,	NULL
monocyte-derived	NULL
macrophages	NULL
,	NULL
and	NULL
differentiated	NULL
UQ937	NULL
cells	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
,	NULL
but	NULL
not	NULL
cytosolic	NULL
fractions	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
contained	NULL
PPARy	NULL
protein	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
this	NULL
band	NULL
as	NULL
PPARy	NULL
was	NULL
supported	NULL
by	NULL
its	NULL
lack	NULL
of	NULL
cytosolic	NULL
expression	NULL
,	NULL
its	NULL
expected	NULL
apparent	NULL
molecular	NULL
weight	NULL
(	NULL
55	NULL
kd	NULL
)	NULL
,	NULL
and	NULL
co-migration	NULL
with	NULL
a	NULL
signal	NULL
in	NULL
fibroblasts	NULL
transfected	NULL
with	NULL
a	NULL
PPARy	NULL
expression	NULL
construct	NULL
.	NULL

Untransfected	NULL
fibroblasts	NULL
demonstrate	NULL
no	NULL
cross-reacting	NULL
band	NULL
of	NULL
the	NULL
appropriate	NULL
size	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

Increased	NULL
PPARy	NULL
Expression	NULL
during	NULL
PMA-induced	NULL
Differentiation	NULL
of	NULL
U937	NULL
Cells	NULL
To	NULL
investigate	NULL
further	NULL
the	NULL
regulation	NULL
of	NULL
PPARy	NULL
during	NULL
differentiation	NULL
of	NULL
cells	NULL
of	NULL
the	NULL
monocytic	NULL
lineage	NULL
,	NULL
U937	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ug/L	NULL
)	NULL
for	NULL
12	NULL
hours	NULL
,	NULL
and	NULL
Northern	NULL
blotting	NULL
was	NULL
performed	NULL
.	NULL

This	NULL
treatment	NULL
increased	NULL
PPARy	NULL
mRNA	NULL
expression	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
showed	NULL
a	NULL
parallel	NULL
rise	NULL
in	NULL
protein	NULL
levels	NULL
in	NULL
nuclear	NULL
fractions	NULL
of	NULL
PMA-treated	NULL
U937	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Neither	NULL
undifferentiated	NULL
nor	NULL
differentiated	NULL
U937	NULL
cells	NULL
demonstrate	NULL
PPARy	NULL
in	NULL
the	NULL
cytosol	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

PPARy	NULL
Activators	NULL
Troglitazone	NULL
and	NULL
PGJ	NULL
,	NULL
;	NULL
Decrease	NULL
Both	NULL
Protein	NULL
Levels	NULL
and	NULL
Gelatinolytic	NULL
Activity	NULL
of	NULL
MMP-9	NULL
Secreted	NULL
from	NULL
Monocyte-Derived	NULL
Macrophages	NULL
To	NULL
elucidate	NULL
the	NULL
functional	NULL
relevance	NULL
of	NULL
PPARy	NULL
activa-tion	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
selective	NULL
PPARy	NULL
activators	NULL
troglitazone	NULL
and	NULL
15	NULL
d-PGJ	NULL
;	NULL
,	NULL
on	NULL
MMP-9	NULL
activity	NULL
in	NULL
monocyte-derived	NULL
macrophages	NULL
.	NULL

Monocytes	NULL
were	NULL
cultured	NULL
initially	NULL
in	NULL
human	NULL
serum	NULL
and	NULL
then	NULL
transferred	NULL
to	NULL
serum-free	NULL
medium	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
troglitazone	NULL
or	NULL
15	NULL
d-PGJ	NULL
,	NULL
.	NULL

Secreted	NULL
MMP-9	NULL
gelatinolytic	NULL
activity	NULL
was	NULL
then	NULL
measured	NULL
using	NULL
substrate	NULL
zymography	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
,	NULL
culture	NULL
of	NULL
monocytes	NULL
for	NULL
6	NULL
days	NULL
with	NULL
human	NULL
serum	NULL
substantially	NULL
increases	NULL
gelatinolytic	NULL
activity	NULL
in	NULL
the	NULL
supernatant	NULL
compared	NULL
with	NULL
freshly	NULL
prepared	NULL
monocytes	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

Concurrent	NULL
treatment	NULL
of	NULL
monocytes	NULL
with	NULL
troglitazone	NULL
or	NULL
15	NULL
d-PGJ	NULL
,	NULL
in	NULL
serum-free	NULL
medium	NULL
during	NULL
this	NULL
transition	NULL
toward	NULL
monocyte-derived	NULL
A	NULL
.	NULL

700	NULL
bp	NULL
-	NULL
>	NULL
500	NULL
bp	NULL
t	NULL
»	NULL
<	NULL
PPARYy	NULL
300	NULL
bp	NULL
-	NULL
#	NULL
»	NULL
(	NULL
473	NULL
bp	NULL
)	NULL
MW	NULL
Mo	NULL
MG	NULL
U937	NULL
Co	NULL
83	NULL
kD	NULL
-	NULL
>	NULL
k	NULL
62	NULL
kD	NULL
-m	NULL
»	NULL
|___	NULL
47.5	NULL
kD	NULL
#	NULL
>	NULL
(	NULL
55	NULL
kD	NULL
)	NULL
*	NULL
+	NULL
-	NULL
-	NULL
Mo	NULL
MG	NULL
U937	NULL
B.	NULL
U937	NULL
288	NULL
-	NULL
>	NULL
$	NULL
188	NULL
--	NULL
<	NULL
4	NULL
PPARy	NULL
(	NULL
1.9	NULL
kb	NULL
)	NULL
Undiff	NULL
.	NULL

Diff	NULL
.	NULL

-	NULL
Undiff	NULL
.	NULL

Diff	NULL
.	NULL

Figure	NULL
2	NULL
.	NULL

A	NULL
:	NULL
PPARy	NULL
mRNA	NULL
and	NULL
protein	NULL
are	NULL
expressed	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
monocyte/macrophage	NULL
lineage	NULL
.	NULL

Upper	NULL
panel	NULL
:	NULL
reverse	NULL
transcription-polymerase	NULL
chain	NULL
reaction	NULL
of	NULL
PPARy	NULL
mRNA	NULL
in	NULL
freshly	NULL
prepared	NULL
monocytes	NULL
(	NULL
Mo	NULL
)	NULL
,	NULL
monocyte-derived	NULL
macrophages	NULL
(	NULL
M	NULL
@	NULL
)	NULL
,	NULL
and	NULL
PMA-differentiated	NULL
U937	NULL
cells	NULL
(	NULL
U937	NULL
)	NULL
reveals	NULL
a	NULL
cDNA	NULL
fragment	NULL
of	NULL
the	NULL
expected	NULL
size	NULL
.	NULL

Also	NULL
shown	NULL
are	NULL
a	NULL
100-bp	NULL
DNA	NULL
ladder	NULL
(	NULL
MW	NULL
)	NULL
and	NULL
negative	NULL
control	NULL
without	NULL
cDNA	NULL
(	NULL
Co	NULL
)	NULL
.	NULL

Lower	NULL
panel	NULL
:	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
PPARy	NULL
protein	NULL
expression	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
freshly	NULL
prepared	NULL
monocytes	NULL
(	NULL
Mo	NULL
)	NULL
,	NULL
monocyte-derived	NULL
macrophages	NULL
(	NULL
MQ	NULL
)	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
(	NULL
U937	NULL
)	NULL
reveals	NULL
a	NULL
band	NULL
of	NULL
the	NULL
appropriate	NULL
size	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
this	NULL
band	NULL
is	NULL
confirmed	NULL
by	NULL
co-migration	NULL
with	NULL
a	NULL
band	NULL
seen	NULL
in	NULL
PPARy-transfected	NULL
human	NULL
skin	NULL
fibroblasts	NULL
(	NULL
+	NULL
)	NULL
but	NULL
not	NULL
in	NULL
similar	NULL
but	NULL
untransfected	NULL
fibroblasts	NULL
(	NULL
-	NULL
)	NULL
.	NULL

All	NULL
results	NULL
shown	NULL
were	NULL
reproduced	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

B	NULL
(	NULL
right	NULL
)	NULL
:	NULL
PPARy	NULL
mRNA	NULL
expression	NULL
in	NULL
undifferentiated	NULL
(	NULL
Undiff	NULL
.	NULL
)	NULL

and	NULL
PMA-differentiated	NULL
U937	NULL
cells	NULL
(	NULL
Diff	NULL
.	NULL
)	NULL

,	NULL
as	NULL
shown	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

Differentiated	NULL
U937	NULL
cells	NULL
show	NULL
increased	NULL
PPARy	NULL
mRNA	NULL
expression	NULL
compared	NULL
with	NULL
undifferentiated	NULL
cells	NULL
.	NULL

B	NULL
(	NULL
left	NULL
)	NULL
:	NULL
Ethidium	NULL
bromide	NULL
staining	NULL
demonstrates	NULL
equal	NULL
loading	NULL
of	NULL
intact	NULL
RNA	NULL
.	NULL

Results	NULL
shown	NULL
were	NULL
reproduced	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

A	NULL
.	NULL

205	NULL
kD	NULL
>	NULL
118	NULL
kD	NULL
--	NULL
85	NULL
kD	NULL
Mo	NULL
MG	NULL
MG	NULL
MQ	NULL
MOG	NULL
MG	NULL
Co	NULL
1	NULL
uM	NULL
5	NULL
uM	NULL
1	NULL
uM	NULL
5	NULL
uM	NULL
B.	NULL
troglitazone	NULL
15d-PGJ	NULL
,	NULL
205	NULL
kD	NULL
>	NULL
118	NULL
kD	NULL
85	NULL
kD	NULL
=	NULL
M4	NULL
MMP-9	NULL
Mo	NULL
_	NULL
MG	NULL
MG	NULL
MO	NULL
MG	NULL
MG	NULL
Co	NULL
1	NULL
uM	NULL
5	NULL
uM	NULL
1	NULL
uM	NULL
5	NULL
uM	NULL
troglitazone	NULL
15d-PGJ	NULL
,	NULL
Macrophages	NULL
in	NULL
Human	NULL
Atheroma	NULL
Express	NULL
PPARy	NULL
-	NULL
21	NULL
AJP	NULL
July	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

153	NULL
,	NULL
No	NULL
.	NULL

1	NULL
macrophages	NULL
inhibited	NULL
the	NULL
increase	NULL
in	NULL
gelatinolytic	NULL
activity	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

Quantification	NULL
of	NULL
gelatinolytic	NULL
areas	NULL
by	NULL
densitometry	NULL
revealed	NULL
a	NULL
reduction	NULL
of	NULL
MMP-9	NULL
activity	NULL
after	NULL
treatment	NULL
with	NULL
troglitazone	NULL
(	NULL
1	NULL
wM	NULL
and	NULL
5	NULL
uM	NULL
)	NULL
to	NULL
73.5	NULL
+	NULL
1.9	NULL
%	NULL
and	NULL
53.3	NULL
+	NULL
12.2	NULL
%	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
with	NULL
15	NULL
d-PGJ	NULL
,	NULL
(	NULL
1	NULL
M	NULL
and	NULL
5	NULL
uM	NULL
)	NULL
to	NULL
79.0	NULL
+	NULL
14.6	NULL
%	NULL
and	NULL
45.5	NULL
+	NULL
8.9	NULL
%	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
both	NULL
cases	NULL
relative	NULL
to	NULL
control	NULL
cells	NULL
{	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
UQ937	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
either	NULL
troglitazone	NULL
or	NULL
15	NULL
d-PGJ	NULL
,	NULL
after	NULL
6	NULL
days	NULL
of	NULL
culture	NULL
in	NULL
human	NULL
serum	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
PPARy	NULL
activation	NULL
was	NULL
required	NULL
during	NULL
differentiation	NULL
for	NULL
inhibition	NULL
of	NULL
MMP-9	NULL
lev-els/activity	NULL
to	NULL
occur	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
the	NULL
observed	NULL
gelatinolytic	NULL
area	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
band	NULL
and	NULL
co-migration	NULL
with	NULL
the	NULL
known	NULL
92-kd	NULL
gelatinolytic	NULL
activity	NULL
in	NULL
PMA-treated	NULL
human	NULL
fibroblast	NULL
supernatants	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
monocyte-derived	NULL
macrophages	NULL
with	NULL
either	NULL
PPAR	NULL
activator	NULL
,	NULL
troglitazone	NULL
or	NULL
15	NULL
d-PGJ	NULL
,	NULL
,	NULL
reduces	NULL
supernatant	NULL
MMP-9	NULL
protein	NULL
levels	NULL
from	NULL
monocyte-derived	NULL
macrophages	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

Co-migration	NULL
with	NULL
the	NULL
known	NULL
MMP-9	NULL
band	NULL
of	NULL
supernatants	NULL
from	NULL
PMA-stimu-lated	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
confirms	NULL
identity	NULL
of	NULL
the	NULL
detected	NULL
band	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

Discussion	NULL
This	NULL
study	NULL
demonstrates	NULL
PPARy	NULL
expression	NULL
in	NULL
macrophages	NULL
in	NULL
human	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
find	NULL
differentiation-dependent	NULL
regulation	NULL
of	NULL
PPARy	NULL
expression	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
monocyte/macrophage	NULL
lineage	NULL
in	NULL
vitro	NULL
.	NULL

Treatment	NULL
of	NULL
differentiated	NULL
monocyte-derived	NULL
macrophages	NULL
in	NULL
vitro	NULL
with	NULL
two	NULL
different	NULL
PPARy	NULL
activators	NULL
,	NULL
15	NULL
d-PGJ	NULL
,	NULL
or	NULL
troglitazone	NULL
,	NULL
decreased	NULL
both	NULL
MMP-9	NULL
protein	NULL
levels	NULL
and	NULL
MMP-9	NULL
gelatinolytic	NULL
activity	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
.	NULL

Coronary	NULL
atherosclerosis	NULL
is	NULL
typically	NULL
a	NULL
diffuse	NULL
pro-cess	NULL
.	NULL

``	NULL
``	NULL
®	NULL
Nevertheless	NULL
,	NULL
despite	NULL
systemic	NULL
risk	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
low-density	NULL
lipoprotein	NULL
levels	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
<	NULL
MMP-9	NULL
Figure	NULL
3	NULL
.	NULL

A	NULL
:	NULL
PPARy	NULL
activators	NULL
decrease	NULL
MMP-9	NULL
gelatinolytic	NULL
activity	NULL
in	NULL
supernatants	NULL
from	NULL
monocyte-derived	NULL
macrophages	NULL
(	NULL
MQ	NULL
)	NULL
in	NULL
a	NULL
concentration-dependent	NULL
fashion	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
zymography	NULL
.	NULL

Monocytes	NULL
were	NULL
cultured	NULL
in	NULL
5	NULL
%	NULL
human	NULL
serum	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
troglitazone	NULL
or	NULL
15	NULL
d-PGJ	NULL
;	NULL
as	NULL
indicated	NULL
.	NULL

Supernatants	NULL
of	NULL
PMA-treated	NULL
fibroblasts	NULL
served	NULL
as	NULL
a	NULL
control	NULL
(	NULL
Co	NULL
)	NULL
.	NULL

Gelatinolytic	NULL
activity	NULL
of	NULL
freshly	NULL
prepared	NULL
monocytes	NULL
is	NULL
also	NULL
shown	NULL
(	NULL
Mo	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
lysates	NULL
were	NULL
loaded	NULL
.	NULL

Results	NULL
shown	NULL
were	NULL
reproduced	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

B	NULL
:	NULL
PPARy	NULL
activators	NULL
decrease	NULL
MMP-9	NULL
protein	NULL
levels	NULL
in	NULL
supernatants	NULL
from	NULL
monocyte-derived	NULL
macrophages	NULL
(	NULL
MQ	NULL
)	NULL
.	NULL

Vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
at	NULL
50	NULL
ug/L	NULL
served	NULL
as	NULL
a	NULL
control	NULL
(	NULL
Co	NULL
)	NULL
.	NULL

Supernatants	NULL
from	NULL
freshly	NULL
prepared	NULL
monocyte	NULL
supernatant	NULL
(	NULL
Mo	NULL
)	NULL
are	NULL
also	NULL
shown	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
reproduced	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

22	NULL
-	NULL
Marx	NULL
et	NULL
al	NULL
AJP	NULL
July	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

153	NULL
,	NULL
No	NULL
.	NULL

1	NULL
macrophages	NULL
and	NULL
inflammatory	NULL
cytokines	NULL
in	NULL
most	NULL
plaques	NULL
,	NULL
some	NULL
arterial	NULL
plaques	NULL
rupture	NULL
,	NULL
whereas	NULL
others	NULL
do	NULL
not	NULL
.	NULL

The	NULL
factors	NULL
accounting	NULL
for	NULL
this	NULL
variability	NULL
are	NULL
unclear	NULL
.	NULL

Certainly	NULL
,	NULL
monocytes/macrophages	NULL
are	NULL
intimately	NULL
involved	NULL
in	NULL
plaque	NULL
rupture	NULL
.	NULL

?	NULL
``	NULL

As	NULL
monocytes	NULL
differentiate	NULL
in	NULL
the	NULL
subintima	NULL
into	NULL
macrophages	NULL
and	NULL
foam	NULL
cells	NULL
,	NULL
the	NULL
atherogenic	NULL
microenvironment	NULL
influences	NULL
transcriptional	NULL
regulation	NULL
of	NULL
genes	NULL
,	NULL
the	NULL
products	NULL
of	NULL
which	NULL
will	NULL
determine	NULL
the	NULL
natural	NULL
history	NULL
of	NULL
the	NULL
lesion	NULL
.	NULL
``	NULL

MMPs	NULL
furnish	NULL
one	NULL
example	NULL
of	NULL
proteins	NULL
,	NULL
the	NULL
induction	NULL
and	NULL
expression	NULL
of	NULL
which	NULL
by	NULL
monocytes/macrophages	NULL
likely	NULL
contributes	NULL
to	NULL
subsequent	NULL
plaque	NULL
rupture	NULL
.	NULL

?	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
indicate	NULL
that	NULL
lesional	NULL
macrophages	NULL
synthesize	NULL
MMPs	NULL
de	NULL
These	NULL
proteins	NULL
are	NULL
enzymatically	NULL
active	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
zymographic	NULL
analysis	NULL
of	NULL
human	NULL
arterial	NULL
spec-imens	NULL
.	NULL
``	NULL

Secretion	NULL
of	NULL
these	NULL
MMPs	NULL
,	NULL
with	NULL
MMP-9	NULL
prominent	NULL
among	NULL
them	NULL
,	NULL
favors	NULL
destabilization	NULL
of	NULL
the	NULL
plaque	NULL
's	NULL
fibrous	NULL
cap	NULL
.	NULL
``	NULL

Our	NULL
findings	NULL
suggest	NULL
that	NULL
PPARy	NULL
,	NULL
as	NULL
a	NULL
nuclear	NULL
transcription	NULL
factor	NULL
present	NULL
in	NULL
lesional	NULL
macrophages	NULL
,	NULL
may	NULL
inhibit	NULL
MMP	NULL
expression	NULL
and	NULL
activity	NULL
.	NULL

Furthermore	NULL
,	NULL
PPARy	NULL
may	NULL
control	NULL
expression	NULL
of	NULL
other	NULL
target	NULL
genes	NULL
within	NULL
the	NULL
arterial	NULL
wall	NULL
,	NULL
thus	NULL
modulating	NULL
a	NULL
cascade	NULL
of	NULL
responses	NULL
in	NULL
monocytes/macrophages	NULL
after	NULL
activation	NULL
by	NULL
its	NULL
endogenous	NULL
or	NULL
synthetic	NULL
ligand	NULL
(	NULL
s	NULL
)	NULL
.	NULL

15	NULL
d-PGJ	NULL
,	NULL
,	NULL
a	NULL
naturally	NULL
occurring	NULL
ligand	NULL
for	NULL
PPARy	NULL
,	NULL
likely	NULL
interacts	NULL
with	NULL
monocytes/macrophages	NULL
.	NULL

J	NULL
;	NULL
,	NULL
prosta-noids	NULL
,	NULL
and	NULL
the	NULL
immediate	NULL
upstream	NULL
precursors	NULL
of	NULL
15	NULL
d-PGJ	NULL
,	NULL
;	NULL
,	NULL
are	NULL
found	NULL
in	NULL
vivo	NULL
.	NULL
``	NULL

''	NULL
Prostaglandins	NULL
themselves	NULL
are	NULL
synthesized	NULL
from	NULL
fatty	NULL
acids	NULL
,	NULL
with	NULL
arachadonic	NULL
acid	NULL
as	NULL
the	NULL
primary	NULL
source	NULL
.	NULL

15	NULL
d-PGD	NULL
,	NULL
,	NULL
the	NULL
major	NULL
prostaglandin	NULL
in	NULL
most	NULL
tissues	NULL
,	NULL
is	NULL
converted	NULL
to	NULL
15	NULL
d-PGJ	NULL
,	NULL
.°2	NULL
This	NULL
process	NULL
requires	NULL
15	NULL
d-PGD	NULL
,	NULL
synthetase	NULL
,	NULL
an	NULL
enzyme	NULL
produced	NULL
primarily	NULL
by	NULL
macrophages	NULL
and	NULL
other	NULL
antigen-presenting	NULL
cells	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
15	NULL
d-PGJ	NULL
,	NULL
,	NULL
acting	NULL
through	NULL
PPARy	NULL
,	NULL
may	NULL
be	NULL
an	NULL
important	NULL
regulator	NULL
of	NULL
macrophage	NULL
function	NULL
.	NULL

Troglitazone	NULL
,	NULL
a	NULL
synthetic	NULL
PPARy	NULL
activator	NULL
,	NULL
is	NULL
currently	NULL
in	NULL
clinical	NULL
use	NULL
as	NULL
an	NULL
antidiabetic	NULL
agent.°*°°	NULL
The	NULL
implications	NULL
of	NULL
its	NULL
effects	NULL
on	NULL
inhibiting	NULL
macrophage	NULL
MMP-9	NULL
matrix	NULL
degradation	NULL
merit	NULL
further	NULL
consideration	NULL
in	NULL
a	NULL
clinical	NULL
context	NULL
.	NULL

A	NULL
very	NULL
recent	NULL
report	NULL
showed	NULL
that	NULL
the	NULL
PPARy	NULL
activator	NULL
15	NULL
d-PGJ	NULL
,	NULL
inhibits	NULL
expression	NULL
of	NULL
an	NULL
MMP-9	NULL
promoter	NULL
luciferase	NULL
construct	NULL
when	NULL
transfected	NULL
into	NULL
U937	NULL
cells	NULL
.	NULL
``	NULL

''	NULL
Our	NULL
findings	NULL
support	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
PPARy	NULL
in	NULL
atherosclerosis	NULL
,	NULL
demonstrating	NULL
its	NULL
presence	NULL
in	NULL
monocytes/macrophages	NULL
of	NULL
human	NULL
atheroma	NULL
and	NULL
increased	NULL
expression	NULL
during	NULL
differentiation	NULL
in	NULL
vifro	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
present	NULL
study	NULL
of	NULL
MMP	NULL
-9	NULL
gelatinolytic	NULL
activity	NULL
illustrates	NULL
directly	NULL
the	NULL
functional	NULL
relevance	NULL
of	NULL
PPARy	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
establish	NULL
a	NULL
rationale	NULL
for	NULL
further	NULL
study	NULL
of	NULL
PPARy	NULL
in	NULL
monocyte/macrophage	NULL
biology	NULL
,	NULL
particularly	NULL
in	NULL
the	NULL
context	NULL
of	NULL
atherosclerosis	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Eugenia	NULL
Schvartz	NULL
for	NULL
her	NULL
expert	NULL
technical	NULL
assistance	NULL
and	NULL
our	NULL
colleagues	NULL
in	NULL
the	NULL
Vascular	NULL
Medicine	NULL
and	NULL
Atherosclerosis	NULL
Unit	NULL
for	NULL
their	NULL
insightful	NULL
technical	NULL
and	NULL
intellectual	NULL
advice	NULL
.	NULL

References	NULL
20	NULL
.	NULL

21.	NULL
.	NULL

Libby	NULL
P	NULL
,	NULL
Geng	NULL
Y	NULL
,	NULL
Aikawa	NULL
M	NULL
,	NULL
Schoenbeck	NULL
U	NULL
,	NULL
Mach	NULL
F	NULL
,	NULL
Clinton	NULL
S	NULL
,	NULL
Sukhova	NULL
G	NULL
,	NULL
Lee	NULL
R	NULL
:	NULL
Macrophages	NULL
and	NULL
atherosclerotic	NULL
plaque	NULL
stability	NULL
.	NULL

Curr	NULL
Opin	NULL
Lipidol	NULL
1996	NULL
,	NULL
7:330-335	NULL
.	NULL

Dollery	NULL
,	NULL
C	NULL
,	NULL
McEwan	NULL
,	NULL
J	NULL
,	NULL
Henney	NULL
,	NULL
A	NULL
:	NULL
Matrix	NULL
metalloproteinases	NULL
and	NULL
cardiovascular	NULL
disease	NULL
.	NULL

Circ	NULL
Res	NULL
1995	NULL
,	NULL
77:863-868	NULL
.	NULL

Davies	NULL
M	NULL
,	NULL
Richardson	NULL
P	NULL
,	NULL
Woolf	NULL
N	NULL
,	NULL
Katz	NULL
D	NULL
,	NULL
Mann	NULL
J	NULL
:	NULL
Risk	NULL
of	NULL
thrombosis	NULL
in	NULL
human	NULL
atherosclerotic	NULL
plaques	NULL
:	NULL
role	NULL
of	NULL
extracellular	NULL
lipid	NULL
,	NULL
macro-phage	NULL
,	NULL
and	NULL
smooth	NULL
muscle	NULL
cells	NULL
content	NULL
.	NULL

Br	NULL
Heart	NULL
J	NULL
1993	NULL
,	NULL
69:377-381	NULL
.	NULL

Lendon	NULL
CL	NULL
,	NULL
Davies	NULL
MJ	NULL
,	NULL
Born	NULL
GV	NULL
,	NULL
Richardson	NULL
PD	NULL
:	NULL
Atherosclerotic	NULL
plaque	NULL
caps	NULL
are	NULL
locally	NULL
weakened	NULL
when	NULL
macrophages	NULL
density	NULL
is	NULL
increased	NULL
.	NULL

Atherosclerosis	NULL
1991	NULL
,	NULL
87:87-90	NULL
.	NULL

Nikkari	NULL
S	NULL
,	NULL
O'Brien	NULL
K	NULL
,	NULL
Ferguson	NULL
M	NULL
,	NULL
Hatsukami	NULL
T	NULL
,	NULL
Welgus	NULL
H	NULL
,	NULL
Clowes	NULL
A	NULL
:	NULL
Interstitial	NULL
collagenase	NULL
(	NULL
MMP-1	NULL
)	NULL
expression	NULL
in	NULL
human	NULL
carotid	NULL
athero-sclerotics	NULL
.	NULL

Circulation	NULL
1995	NULL
,	NULL
92:1393-1398	NULL
.	NULL

Galis	NULL
Z	NULL
,	NULL
Sukhova	NULL
G	NULL
,	NULL
Lark	NULL
M	NULL
,	NULL
Libby	NULL
P	NULL
:	NULL
Increased	NULL
expression	NULL
of	NULL
matrix	NULL
metalloproteinases	NULL
and	NULL
matrix	NULL
degradation	NULL
activity	NULL
in	NULL
vulnerable	NULL
regions	NULL
of	NULL
human	NULL
atherosclerotic	NULL
plaques	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
1994	NULL
,	NULL
94:2493-2503	NULL
.	NULL

Goetzl	NULL
E	NULL
,	NULL
Banda	NULL
M	NULL
,	NULL
Leppert	NULL
D	NULL
:	NULL
Matrix	NULL
metalloproteinases	NULL
in	NULL
immunity	NULL
.	NULL

J	NULL
Immunol	NULL
1996	NULL
,	NULL
156:1-4	NULL
.	NULL

Welgus	NULL
H	NULL
,	NULL
Campbell	NULL
E	NULL
,	NULL
Cury	NULL
J	NULL
,	NULL
Eisen	NULL
A	NULL
,	NULL
Senior	NULL
RM	NULL
,	NULL
Goldberg	NULL
G	NULL
:	NULL
Neutral	NULL
-	NULL
metalloproteinases	NULL
produced	NULL
by	NULL
human	NULL
mononuclear	NULL
phagocytes	NULL
:	NULL
enzyme	NULL
profile	NULL
,	NULL
regulation	NULL
,	NULL
and	NULL
expression	NULL
during	NULL
cellular	NULL
development	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
1990	NULL
,	NULL
86:1496-1502	NULL
.	NULL

Saren	NULL
P	NULL
,	NULL
Welgus	NULL
H	NULL
,	NULL
Kovanen	NULL
P	NULL
:	NULL
TNF-a	NULL
and	NULL
IL-1B	NULL
selectively	NULL
induce	NULL
expression	NULL
of	NULL
92-kd	NULL
gelatinase	NULL
by	NULL
human	NULL
macrophages	NULL
.	NULL

J	NULL
Immunol	NULL
1996	NULL
,	NULL
157:4159-4165	NULL
.	NULL

Schoenbeck	NULL
U	NULL
,	NULL
Mach	NULL
F	NULL
,	NULL
Sukhova	NULL
G	NULL
,	NULL
Murphy	NULL
C	NULL
,	NULL
Bonnefoy	NULL
J-Y	NULL
,	NULL
Fabunmi	NULL
R	NULL
,	NULL
Libby	NULL
P	NULL
:	NULL
Regulation	NULL
of	NULL
matrix	NULL
metalloproteinase	NULL
expression	NULL
in	NULL
human	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
by	NULL
T	NULL
lymphocytes	NULL
.	NULL

Circ	NULL
Res	NULL
1997	NULL
,	NULL
81:448-454	NULL
.	NULL

Schroen	NULL
DJ	NULL
,	NULL
Brinckerhoff	NULL
C	NULL
:	NULL
Nuclear	NULL
hormone	NULL
receptors	NULL
inhibit	NULL
matrix	NULL
metalloproteinases	NULL
(	NULL
MMP	NULL
)	NULL
gene	NULL
expression	NULL
through	NULL
diverse	NULL
mecha-nisms	NULL
.	NULL

Gene	NULL
Exp	NULL
1996	NULL
,	NULL
6:197-207	NULL
.	NULL

Schoonjans	NULL
K.	NULL
,	NULL
Martin	NULL
G	NULL
,	NULL
Staels	NULL
B	NULL
,	NULL
Auwerx	NULL
J	NULL
:	NULL
Peroxisome	NULL
proliferator	NULL
activated	NULL
receptors	NULL
,	NULL
orphans	NULL
with	NULL
ligands	NULL
and	NULL
functions	NULL
.	NULL

Curr	NULL
Opin	NULL
Lipidol	NULL
1997	NULL
,	NULL
8:159-166	NULL
.	NULL

Vidal-Puig	NULL
AJ	NULL
,	NULL
Considine	NULL
RV	NULL
,	NULL
Jimenez-Linan	NULL
MA	NULL
,	NULL
Pories	NULL
WJ	NULL
,	NULL
Caro	NULL
JF	NULL
,	NULL
Flier	NULL
JS	NULL
:	NULL
Peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
tissues	NULL
:	NULL
effects	NULL
of	NULL
obesity	NULL
,	NULL
weight	NULL
loss	NULL
,	NULL
and	NULL
regulation	NULL
by	NULL
insulin	NULL
and	NULL
glucocorticoids	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
1997	NULL
,	NULL
99:2416-2422	NULL
.	NULL

Tontonoz	NULL
P	NULL
,	NULL
Hu	NULL
E	NULL
,	NULL
Spiegelman	NULL
BM	NULL
:	NULL
Stimulation	NULL
of	NULL
adipogenesis	NULL
in	NULL
fibroblasts	NULL
by	NULL
PPAR	NULL
y2	NULL
,	NULL
a	NULL
lipid-activated	NULL
transcription	NULL
factor	NULL
.	NULL

Cell	NULL
1994	NULL
,	NULL
79:1147-1156	NULL
.	NULL

Brun	NULL
R	NULL
,	NULL
Tontonoz	NULL
P	NULL
,	NULL
Forman	NULL
B	NULL
,	NULL
Ellis	NULL
RJ	NULL
,	NULL
Evan	NULL
R	NULL
,	NULL
Spiegelman	NULL
BM	NULL
:	NULL
Differential	NULL
activation	NULL
of	NULL
adipogenesis	NULL
by	NULL
multiple	NULL
PPAR	NULL
isoforms	NULL
.	NULL

Genes	NULL
Dev	NULL
1996	NULL
,	NULL
10:974-984	NULL
.	NULL

Mangelsdorf	NULL
DJ	NULL
,	NULL
Thummel	NULL
C	NULL
,	NULL
Beato	NULL
M	NULL
,	NULL
Herrlich	NULL
P	NULL
,	NULL
Schutz	NULL
G	NULL
,	NULL
Ume-	NULL
sono	NULL
K	NULL
,	NULL
Blumberg	NULL
B	NULL
,	NULL
Kastner	NULL
P	NULL
,	NULL
Mark	NULL
M	NULL
,	NULL
Chambon	NULL
P	NULL
,	NULL
Evans	NULL
R	NULL
:	NULL
The	NULL
nuclear	NULL
receptor	NULL
superfamily	NULL
:	NULL
the	NULL
second	NULL
decade	NULL
.	NULL

Cell	NULL
1995	NULL
,	NULL
83:835-839	NULL
.	NULL

Forman	NULL
,	NULL
BM	NULL
.	NULL

,	NULL
Tontonoz	NULL
P	NULL
,	NULL
Chen	NULL
J	NULL
,	NULL
Brun	NULL
RP	NULL
,	NULL
Spiegelman	NULL
BM	NULL
,	NULL
Evans	NULL
R	NULL
:	NULL
M.	NULL
15-Deoxy-delta	NULL
12,14-prostaglandin	NULL
J2	NULL
is	NULL
a	NULL
ligand	NULL
for	NULL
the	NULL
adipocyte	NULL
determination	NULL
factor	NULL
PPAR	NULL
y	NULL
.	NULL

Cell	NULL
1995	NULL
,	NULL
83:803-812	NULL
.	NULL

Kliewer	NULL
SA	NULL
,	NULL
.	NULL

Lenhard	NULL
JM	NULL
,	NULL
Willson	NULL
TM	NULL
,	NULL
Patel	NULL
I	NULL
,	NULL
Morris	NULL
D	NULL
,	NULL
Lehmann	NULL
JM	NULL
:	NULL
A	NULL
prostaglandin	NULL
J2	NULL
metabolite	NULL
binds	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
y	NULL
and	NULL
promotes	NULL
adipocyte	NULL
differentiation	NULL
.	NULL

Cell	NULL
1995	NULL
,	NULL
83:813-819	NULL
.	NULL

Yu	NULL
K	NULL
,	NULL
Bayona	NULL
W	NULL
,	NULL
Kallen	NULL
CB	NULL
,	NULL
Harding	NULL
HP	NULL
,	NULL
Ravera	NULL
CP	NULL
,	NULL
McMahon	NULL
G	NULL
,	NULL
Brown	NULL
M	NULL
,	NULL
Lazar	NULL
MA	NULL
:	NULL
Differential	NULL
activation	NULL
of	NULL
peroxisome	NULL
proliferator-activated	NULL
receptors	NULL
by	NULL
eicosanoids	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1995	NULL
,	NULL
270:23975-23983	NULL
Lehmann	NULL
JM	NULL
,	NULL
Moore	NULL
LB	NULL
,	NULL
Smith-Oliver	NULL
TA	NULL
,	NULL
Wilkison	NULL
WO	NULL
,	NULL
Willson	NULL
TM	NULL
,	NULL
Kliewer	NULL
SA	NULL
:	NULL
An	NULL
antidiabetic	NULL
thiazolidinedione	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
ligand	NULL
for	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
y.	NULL
J	NULL
Biol	NULL
Chem	NULL
1995	NULL
,	NULL
270:12953-12956	NULL
Willson	NULL
TM	NULL
,	NULL
Cobb	NULL
JE	NULL
,	NULL
Cowan	NULL
DJ	NULL
,	NULL
Wiethe	NULL
RW	NULL
,	NULL
Correa	NULL
ID	NULL
,	NULL
Prakash	NULL
SR	NULL
,	NULL
Beck	NULL
KD	NULL
,	NULL
Moore	NULL
LB	NULL
,	NULL
Kliewer	NULL
SA	NULL
,	NULL
Lehmann	NULL
JM	NULL
:	NULL
The	NULL
structure-activity	NULL
relationship	NULL
between	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
y	NULL
agonism	NULL
and	NULL
the	NULL
antinyperglycemic	NULL
activity	NULL
of	NULL
thiazolidinediones	NULL
.	NULL

J	NULL
Med	NULL
Chem	NULL
1996	NULL
,	NULL
39:665-668	NULL
22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

Kliewer	NULL
SA	NULL
,	NULL
Sundseth	NULL
SS	NULL
,	NULL
Jones	NULL
SA	NULL
,	NULL
Brown	NULL
PJ	NULL
,	NULL
Wisely	NULL
GB	NULL
,	NULL
Koble	NULL
CS	NULL
,	NULL
Devchand	NULL
P	NULL
,	NULL
Wahli	NULL
W	NULL
,	NULL
Willson	NULL
TM	NULL
,	NULL
Lenhard	NULL
JM	NULL
,	NULL
Lehmann	NULL
JM	NULL
:	NULL
Fatty	NULL
acids	NULL
and	NULL
eicosanoids	NULL
regulate	NULL
gene	NULL
expression	NULL
through	NULL
direct	NULL
interactions	NULL
with	NULL
peroxisome	NULL
proliferator-activated	NULL
receptors	NULL
a	NULL
and	NULL
y.	NULL
Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1997	NULL
,	NULL
94:4318-4323	NULL
Greene	NULL
M	NULL
,	NULL
Blumberg	NULL
B	NULL
,	NULL
McBride	NULL
O	NULL
,	NULL
Kronquist	NULL
K	NULL
,	NULL
Kwan	NULL
K	NULL
,	NULL
Hsigh	NULL
L	NULL
,	NULL
Greene	NULL
G	NULL
,	NULL
Nimer	NULL
S	NULL
:	NULL
Isolation	NULL
of	NULL
the	NULL
human	NULL
peroxisome	NULL
proliferator	NULL
activated	NULL
receptor	NULL
y	NULL
cDNA	NULL
:	NULL
expression	NULL
in	NULL
hematopoietic	NULL
cells	NULL
and	NULL
chromosomal	NULL
mapping	NULL
.	NULL

Gene	NULL
Expression	NULL
1995	NULL
,	NULL
4:281-299	NULL
Jiang	NULL
C	NULL
,	NULL
Ting	NULL
A	NULL
,	NULL
Seed	NULL
B	NULL
:	NULL
PPAR-y	NULL
agonists	NULL
inhibit	NULL
production	NULL
of	NULL
monocyte	NULL
inflammatory	NULL
cytokines	NULL
.	NULL

Nature	NULL
1998	NULL
,	NULL
391	NULL
:	NULL
82-86	NULL
Ricote	NULL
M	NULL
,	NULL
Li	NULL
A	NULL
,	NULL
Wilson	NULL
T	NULL
,	NULL
Kelly	NULL
C	NULL
,	NULL
Glass	NULL
C	NULL
:	NULL
The	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor-y	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
macrophage	NULL
acti-vation	NULL
.	NULL

Nature	NULL
1998	NULL
,	NULL
391:79-82	NULL
Ross	NULL
R	NULL
:	NULL
The	NULL
pathogenesis	NULL
of	NULL
atherosclerosis	NULL
:	NULL
a	NULL
perspective	NULL
for	NULL
the	NULL
1990s	NULL
.	NULL

Nature	NULL
1993	NULL
,	NULL
362:801-809	NULL
Raines	NULL
E	NULL
,	NULL
Ross	NULL
R	NULL
:	NULL
Is	NULL
overamplification	NULL
of	NULL
the	NULL
normal	NULL
macrophage	NULL
defensive	NULL
role	NULL
critical	NULL
to	NULL
lesion	NULL
development	NULL
?	NULL

Ann	NULL
NY	NULL
Acad	NULL
Sci	NULL
1997	NULL
,	NULL
811:76-85	NULL
Galis	NULL
Z	NULL
,	NULL
Sukhova	NULL
G	NULL
,	NULL
Kranzhosfer	NULL
R	NULL
,	NULL
Clark	NULL
S	NULL
,	NULL
Libby	NULL
P	NULL
:	NULL
Macrophage	NULL
foam	NULL
cells	NULL
from	NULL
experimental	NULL
atheroma	NULL
constitutively	NULL
produce	NULL
matrix-degrading	NULL
proteinases	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1995	NULL
,	NULL
92:402-406	NULL
Henney	NULL
A	NULL
,	NULL
Wakeley	NULL
P	NULL
,	NULL
Davies	NULL
M	NULL
,	NULL
Foster	NULL
K	NULL
,	NULL
Hembry	NULL
R	NULL
,	NULL
Murphy	NULL
G	NULL
,	NULL
30	NULL
.	NULL

31	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

Macrophages	NULL
in	NULL
Human	NULL
Atheroma	NULL
Express	NULL
PPARy	NULL
-	NULL
23	NULL
AJP	NULL
July	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

153	NULL
,	NULL
No	NULL
.	NULL

1	NULL
Humphries	NULL
S	NULL
:	NULL
Localization	NULL
of	NULL
stromelysin	NULL
gene	NULL
expression	NULL
in	NULL
atherosclerotic	NULL
plaques	NULL
by	NULL
in	NULL
situ	NULL
hybridization	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1991	NULL
,	NULL
88:8154-8158	NULL
Galis	NULL
Z	NULL
,	NULL
Sukhova	NULL
G	NULL
,	NULL
Libby	NULL
P	NULL
:	NULL
Microscopic	NULL
localization	NULL
of	NULL
active	NULL
pro-teases	NULL
by	NULL
in	NULL
situ	NULL
zymography	NULL
:	NULL
detection	NULL
of	NULL
matrix	NULL
metalloproteinase	NULL
activity	NULL
in	NULL
vascular	NULL
tissue	NULL
.	NULL

FASEB	NULL
J	NULL
1995	NULL
,	NULL
9:974-980	NULL
Fukushima	NULL
M	NULL
:	NULL
Biological	NULL
activities	NULL
and	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
PGJ	NULL
;	NULL
and	NULL
related	NULL
compounds	NULL
:	NULL
an	NULL
update	NULL
.	NULL

Prostaglandins	NULL
Leukotrienes	NULL
Essent	NULL
Fatty	NULL
Acids	NULL
1992	NULL
,	NULL
47:1-12	NULL
.	NULL

Giles	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Leff	NULL
,	NULL
P	NULL
:	NULL
The	NULL
biology	NULL
and	NULL
pharmacology	NULL
of	NULL
PGDs	NULL
.	NULL

Prostaglandins	NULL
1988	NULL
,	NULL
35:277-300	NULL
Urade	NULL
Y	NULL
,	NULL
Ufinara	NULL
M	NULL
,	NULL
Horigushi	NULL
Y	NULL
,	NULL
Ikai	NULL
K	NULL
,	NULL
Hayaishi	NULL
O	NULL
:	NULL
The	NULL
major	NULL
source	NULL
of	NULL
endogenous	NULL
prostaglandin	NULL
D2	NULL
is	NULL
likely	NULL
antigen-presenting	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1989	NULL
,	NULL
143:2982-2989	NULL
Nolen	NULL
J	NULL
,	NULL
Ludvik	NULL
B	NULL
,	NULL
Beerdsen	NULL
P	NULL
:	NULL
Improvement	NULL
in	NULL
glucose	NULL
tolerance	NULL
and	NULL
insulin	NULL
resistance	NULL
in	NULL
obese	NULL
subjects	NULL
treated	NULL
with	NULL
troglitazone	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
1994	NULL
,	NULL
331:1188-1193	NULL
Inzucchi	NULL
SE	NULL
,	NULL
Maggs	NULL
DG	NULL
,	NULL
Spollett	NULL
GR	NULL
,	NULL
Page	NULL
SL	NULL
,	NULL
Rife	NULL
FS	NULL
,	NULL
Walton	NULL
V	NULL
,	NULL
Shulman	NULL
GI	NULL
:	NULL
Efficacy	NULL
and	NULL
metabolic	NULL
effects	NULL
of	NULL
merformin	NULL
and	NULL
troglitazone	NULL
in	NULL
type	NULL
II	NULL
diabetes	NULL
mellitus	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
1998	NULL
,	NULL
338:867-872	NULL
Schwartz	NULL
S	NULL
,	NULL
Raskin	NULL
P	NULL
,	NULL
Fonseca	NULL
V	NULL
,	NULL
Graveline	NULL
JF	NULL
:	NULL
Effect	NULL
of	NULL
troglitazone	NULL
in	NULL
insulin-treated	NULL
patients	NULL
with	NULL
type	NULL
|I	NULL
diabetes	NULL
mellitus	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
1998	NULL
,	NULL
338:861-866	NULL

